Abstract
Cardiovascular disease is becoming an increasingly significant problem. In attempts to overcome many of the traditional hurdles of cardiovascular disease treatment, therapeutic approaches have been gradually moving beyond an exclusive focus on orally delivered drugs towards the development of nanoscale applications. These technologies exploit molecular scale events to improve drug and gene delivery applications, enhance preventative medicine and diagnostic strategies, and create biomimicking substrates for vascular tissue engineering. As nanoscale treatments enter the arena of clinical medicine, new ways of thinking about and routes for applying nanomedicine to cardiovascular health issues are emerging. With focuses on drug delivery, gene therapy, and biomimetics, this article will provide a comprehensive review of various nanomedicine applications for combating atherosclerosis and for improving upon current vascular tissue engineering designs.
Current Bioactive Compounds
Title: Nanomedicine: Addressing Cardiovascular Disease and Cardiovascular Tissue Regeneration
Volume: 5 Issue: 3
Author(s): Rebekah A. Neal, Olugbemisola Oredein-McCoy and Edward A. Botchwey
Affiliation:
Abstract: Cardiovascular disease is becoming an increasingly significant problem. In attempts to overcome many of the traditional hurdles of cardiovascular disease treatment, therapeutic approaches have been gradually moving beyond an exclusive focus on orally delivered drugs towards the development of nanoscale applications. These technologies exploit molecular scale events to improve drug and gene delivery applications, enhance preventative medicine and diagnostic strategies, and create biomimicking substrates for vascular tissue engineering. As nanoscale treatments enter the arena of clinical medicine, new ways of thinking about and routes for applying nanomedicine to cardiovascular health issues are emerging. With focuses on drug delivery, gene therapy, and biomimetics, this article will provide a comprehensive review of various nanomedicine applications for combating atherosclerosis and for improving upon current vascular tissue engineering designs.
Export Options
About this article
Cite this article as:
Neal A. Rebekah, Oredein-McCoy Olugbemisola and Botchwey A. Edward, Nanomedicine: Addressing Cardiovascular Disease and Cardiovascular Tissue Regeneration, Current Bioactive Compounds 2009; 5 (3) . https://dx.doi.org/10.2174/157340709789054722
DOI https://dx.doi.org/10.2174/157340709789054722 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High Levels of Serum Uric Acid, Cystain C and Lipids Concentration and their Clinical Significance in Primary Gouty Arthritis Patients
Current Rheumatology Reviews Early Prediction of Preeclampsia: Hope for Early Intervention?
Current Women`s Health Reviews A Review on the Role of Phytosterols: New Insights Into Cardiovascular Risk
Current Pharmaceutical Design Folic Acid, Neurodegenerative and Neuropsychiatric Disease
Current Molecular Medicine Dysglycemia and Abdominal Obesity
Current Vascular Pharmacology Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design The Effects of Direct Renin Inhibitor, Aliskiren, on Arterial Hypertension, Chronic Kidney Disease and Cardiovascular Disease: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry Medical Treatment of Peripheral Arterial Disease: Current Concepts and Future Options
Vascular Disease Prevention (Discontinued) MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome
Medicinal Chemistry Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot Topic: Trends in Vascular Biology; Functional Restoration of Damaged Endothelium (Executive Editors: J.A. Rodriguez-Feo and G. Pasterkamp)]
Current Pharmaceutical Design Experimental Benefits of Sex Hormones on Vascular Function and the Outcome of Hormone Therapy in Cardiovascular Disease
Current Cardiology Reviews